甲磺酸阿帕替尼片治疗晚期非小细胞肺癌的临床效果分析  

Analysis on the clinical effect of apatinib mesylate tablet in the treatment of advanced non-small cell lung cancer

作　　者：金元虹[1] 潘炯伟[1] JIN Yuanhong;PAN Jiongwei(Department of Respiratory Medicine,Lishui People’s Hospital in Zhejiang Province,Lishui 323000,China)

机构地区：[1]浙江省丽水市人民医院呼吸内科,浙江丽水323000

出　　处：《中国现代医生》2019年第10期112-115,共4页China Modern Doctor

基　　金：浙江省科技计划项目(2016C33243)

摘　　要：目的探讨晚期非小细胞肺癌患者应用甲磺酸阿帕替尼片治疗的效果。方法选取2015年1月～2017年5月于我院行化疗的晚期非小细胞肺癌患者55例,其中应用紫杉醇联合顺铂治疗的27例患者为常规组,加用甲磺酸阿帕替尼治疗的28例患者为干预组。观察患者的治疗效果、相关指标变化、不良反应及生存质量。结果干预组患者的ORR、DCR、不良反应总发生率及生存质量均高于常规组(P<0.05);两组患者治疗后的CEA、VEGF和MMP-9水平均低于治疗前(P<0.05),且干预组患者治疗后CEA、VEGF和MMP-9水平更低(P<0.05)。结论甲磺酸阿帕替尼治疗晚期非小细胞肺癌的临床效果显著。Objective To investigate the effect of lapatinib mesylate tablets in the patients with advanced non-small cell lung cancer.Methods A total of 55 patients with advanced non-small cell lung cancer who were given chemoth·erapy in our hospital from January 2015 to May 2017 were selected.Among them,27 patients who were given paclitaxel combined with cisplatin for treatment were assigned to the conventional group.28 patients who were given apatinib mesylate for treatment were assigned to the intervention group.The patient's therapeutic effect,related index changes,adverse reactions and quality of life were observed.Results ORR,DCR,total incidence rate of adverse reactions and quality of life in the intervention group were higher than those in the conventional group(P<0.05);the levels of CEA,VEGF and MMP-9 in the two groups after treatment were lower than those before treatment(P<0.05).Patients in the intervention group had lower levels of CEA,VEGF,and MMP-9 after treatment(P<0.05).Conclusion The clinical effect of lapatinib mesylate in the treatment of advanced non-small cell lung cancer is significant.

关 键 词：肺癌 非小细胞肺癌 晚期 甲磺酸阿帕替尼 

分 类 号：R734.2[医药卫生—肿瘤]